Perkins Capital Management Inc Neu Base Therapeutics, Inc. Transaction History

Perkins Capital Management Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	BUY	$0.17 - $0.39 $5,695 - $13,065	33,500 Added 33.84%	132,500 $25,000
Q4 2022 Jan 26, 2023	BUY	$0.18 - $0.3 $180 - $300	1,000 Added 1.02%	99,000 $19,000
Q3 2022 Oct 24, 2022	BUY	$0.41 - $1.3 $6,765 - $21,450	16,500 Added 20.25%	98,000 $39,000
Q2 2022 Jul 29, 2022	BUY	$0.82 - $1.93 $12,300 - $28,950	15,000 Added 22.56%	81,500 $86,000
Q1 2022 Apr 20, 2022	BUY	$1.26 - $2.95 $45,990 - $107,675	36,500 Added 121.67%	66,500 $125,000
Q4 2021 Feb 10, 2022	BUY	$2.6 - $4.18 $23,400 - $37,620	9,000 Added 42.86%	30,000 $84,000
Q3 2021 Oct 25, 2021	BUY	$3.27 - $4.76 $20,274 - $29,512	6,200 Added 41.89%	21,000 $76,000
Q2 2021 Jul 28, 2021	BUY	$4.63 - $7.34 $68,524 - $108,632	14,800 New	14,800 $71,000

Ticker NBSE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,258,700
Description
NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as ...

Get notified when there are updates to the investment portfolio of Perkins Capital Management Inc, based on Form 13F filings with the SEC.

Stay updated on Perkins Capital Management Inc with notifications on news.